Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gossamer Bio, Inc.GOSS · Entity 6928 | Chief Development Officer | August 24, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gossamer Bio, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2036-08-23 | Direct | 5,800,051 |
Reported balance
After 2026-08-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-24 · Grant · Acquired 5,800,051 · Balance 5,800,051 F1: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 25, 2021 Filed Oct 26, 2021 21:08 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 2,377 | $12.25 | $29,118.25 |
DisclosureSEC source: 0001728117-21-000100 · wf-form4_163528246970845.xml · nonDerivative · entry 1 Peterson Caryn · CIK 0001857256 · EVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,451 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 22:07 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 31,750 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001728117-21-000040 · wf-form4_161895639999354.xml · derivative · entry 2 Peterson Caryn · CIK 0001857256 · EVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,750 Underlying: Common Stock · 31,750 shares Expires 2031-04-16 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on April 16, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 22:07 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 10,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000040 · wf-form4_161895639999354.xml · nonDerivative · entry 1 Peterson Caryn · CIK 0001857256 · EVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,828 F1 · shares: Represents a restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.